LCAR-M61SQ in Treatment of Relapsed/Refractory Multiple Myeloma

NANot yet recruitingINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

March 20, 2025

Primary Completion Date

June 30, 2030

Study Completion Date

December 30, 2030

Conditions
Relapsed/Refractory Multiple Myeloma
Interventions
BIOLOGICAL

Cell injection

LCAR-M61SQ cells intravenous infusion; Prior to infusion of the LCAR-M61SQ cell, Subjects will receive a conditioning premedication regimen consisting of cyclophosphamide and fludarabine.

All Listed Sponsors
collaborator

Beijing Boren Hospital

OTHER

collaborator

First People's Hospital of Hangzhou

OTHER

lead

First Affiliated Hospital of Wenzhou Medical University

OTHER